Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023)
Mira Pharmaceuticals' (MIRA) quarterly Total Non-Current Liabilities came in at $558097.0 in Q4 2023, down 58.79% year-on-year from $1.4 million in Q4 2022, and down 58.79% quarter-over-quarter from $1.4 million in Q4 2022.
Mira Pharmaceuticals (MIRA) Total Non-Current Liabilities (2022 - 2023) Analysis & Trends
Mira Pharmaceuticals has disclosed Total Non-Current Liabilities across 2 years of filings, most recently posting $558097.0 for Q4 2023.
- Total Non-Current Liabilities for Q4 2023 came in at $558097.0, down 58.79% year-over-year; the trailing twelve-month figure through Dec 2023 was $558097.0 (down 58.79% YoY), and the FY2023 annual result was $558097.0, down 58.79% from the prior year.
- Total Non-Current Liabilities came in at $558097.0 for Q4 2023 at Mira Pharmaceuticals, down from $1.4 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.4 million in Q4 2022 to a low of $558097.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -31.03 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 48.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.22 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 108.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 75.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 61.52 Bn |
| 10 | Mira Pharmaceuticals | 23.69 Mn | 12.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 558,097.00 |
| Dec 31, 2022 | 1.35 Mn |